Holen Sie sich die Stockscreener-App
37.48
7.62%
-3.09
Handel nachbörslich:
37.01
-0.47
-1.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$40.57
Offen:
$40.75
24-Stunden-Volumen:
1.11M
Relative Volume:
1.63
Marktkapitalisierung:
$1.39B
Einnahmen:
$154.15M
Nettoeinkommen (Verlust:
$-33.58M
KGV:
-39.04
EPS:
-0.96
Netto-Cashflow:
$-20.74M
1W Leistung:
-17.50%
1M Leistung:
-3.58%
6M Leistung:
+59.66%
1J Leistung:
-24.54%
1-Tages-Spanne:
$37.39
$41.08
1-Wochen-Bereich:
$37.39
$45.41
52-Wochen-Spanne:
$20.85
$59.23
Harrow Inc Stock (HROW) Company Profile
Firmenname
Harrow Inc
Sektor
Telefon
615.733.4731
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Vergleichen Sie HROW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
37.48 | 1.50B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | BTIG Research | Buy |
| 2025-06-10 | Eingeleitet | William Blair | Outperform |
| 2025-02-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-04 | Bestätigt | B. Riley Securities | Buy |
| 2024-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2022-09-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-09-24 | Eingeleitet | Aegis Capital | Buy |
| 2021-07-02 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Harrow Inc Aktie (HROW) Neueste Nachrichten
Is it too late to sell Harrow Inc.Earnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
What data driven models say about Harrow Inc.’s futurePortfolio Risk Report & Weekly High Conviction Trade Ideas - newser.com
What institutional flow reveals about Harrow Inc.Dollar Strength & Entry and Exit Point Strategies - newser.com
Using data tools to time your Harrow Inc. exitJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Harrow (NASDAQ:HROW) - MarketBeat
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
Will Harrow's (HROW) Affordability Push and New Leadership Shift its Long-Term Growth Trajectory? - simplywall.st
Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage? - Yahoo Finance
ImprimisRx Announces Leadership Changes - GlobeNewswire
Is Harrow Inc. stock dividend yield sustainableWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Harrow names Frank Mullery as CEO of ImprimisRx subsidiary - Investing.com
Harrow Health (HROW) Appoints New Leadership at ImprimisRx - GuruFocus
Harrow Health Announces New Leadership at ImprimisRx - TipRanks
Harrow names Frank Mullery as CEO of ImprimisRx subsidiary By Investing.com - Investing.com Canada
ImprimisRx announces leadership changes - MarketScreener
Leadership Appointments at ImprimisRx: Frank Mullery Named CEO and Bridseida Cruz as Head of Quality - Quiver Quantitative
Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary - Stock Titan
Intraday pattern recognizer results for Harrow Inc.Bull Run & Technical Pattern Recognition Alerts - newser.com
How to escape a deep drawdown in Harrow Inc.July 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
Assessing Harrow’s Value After a 22.8% Surge and Recent Earnings Release - simplywall.st
How to track smart money flows in Harrow Inc.Market Volume Report & Smart Money Movement Alerts - newser.com
Harrow (NASDAQ:HROW) Trading Down 4.9%Should You Sell? - MarketBeat
A Fresh Look at Harrow (HROW) Valuation Following Recent Share Price Momentum - simplywall.st
Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump - simplywall.st
Research Analysts Issue Forecasts for Harrow Q3 Earnings - MarketBeat
How to use Fibonacci retracement on Harrow Inc.2025 Top Gainers & High Yield Stock Recommendations - newser.com
B. Riley Comments on Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
B. Riley Securities Reiterates Harrow (HROW) Buy Recommendation - Nasdaq
HROW: B. Riley Securities Increases Price Target to $74, Reitera - GuruFocus
Harrow to purchase Melt Pharmaceuticals - Eyes On Eyecare
B. Riley Adjusts Price Target on Harrow to $74 From $70, Maintains Buy Rating - MarketScreener
William Blair Issues Positive Outlook for Harrow Earnings - MarketBeat
What is William Blair's Estimate for Harrow FY2025 Earnings? - MarketBeat
Lake Street Maintains Harrow (HROW) Buy Recommendation - Nasdaq
Harrow (NASDAQ:HROW) Shares Gap UpStill a Buy? - MarketBeat
HROW Analyst Update: Lake Street Raises Price Target to $70 | HR - GuruFocus
H.C. Wainwright reiterates Buy rating on Harrow Health stock, maintains $64 target - Investing.com Australia
HC Wainwright Reaffirms Buy Rating for Harrow (NASDAQ:HROW) - MarketBeat
Finanzdaten der Harrow Inc-Aktie (HROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harrow Inc-Aktie (HROW) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
| SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
| BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
1.54%
1.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):